FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study
SourceNephrology, Dialysis, Transplantation, 26, 11, (2011), pp. 3802-3805
Article / Letter to editor
Display more detailsDisplay less details
Nephrology, Dialysis, Transplantation
SubjectN4i 4: Auto-immunity, transplantation and immunotherapy
BACKGROUND: FTY720 (fingolimod), a novel immunomodulator, has demonstrated potential for prevention of acute rejection in combination with cyclosporine. METHODS: This study evaluated FTY720 2.5 mg versus mycophenolate mofetil (MMF) in a combination regimen with standard tacrolimus and corticosteroids in de novo renal transplant recipients for the composite efficacy within 6 months of transplantation. RESULTS: Incidence of treated biopsy-proven acute rejection was 22.9% with FTY720 and 18.5% with MMF. Increased incidence of macular oedema, transient decrease in heart rate and low rate of infections were seen in the FTY720 arm. CONCLUSION: FTY720 combined with tacrolimus and steroids did not show a significant therapeutic advantage over MMF for the prevention of acute rejection in de novo renal transplant recipients.
Upload full text